Title: Dong-A Ilbo– LegoChem opens up the future with next generation platform technology.

Publication: Dong-A Ilbo                                        

Date: 01 October 2011

Summary

• Employees of LegoChem work until late night but show lower turnover rate than any other companies. CEO Yong Zu Kim founds the reason in honest and moral management.

• ADC is not a candidate substance for a new drug but a platform technology for drug R&D that can innovatively improve drawbacks of the first generation technology,

• CEO of LegoChem, Dr. Yong Zu Kim emphasized that his employees are very competitive in drug development with accumulated experience and knowledge. He also explained “LegoChem has a goal to develop core technology and system that can fulfill the global standard and will grow into a global drug development company.”

   

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).